Advanced Malignant Solid Neoplasm Clinical Trials

29 recruiting

Advanced Malignant Solid Neoplasm Trials at a Glance

37 actively recruiting trials for advanced malignant solid neoplasm are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 20 trials, with the heaviest enrollment activity in Houston, Bethesda, and Chicago. Lead sponsors running advanced malignant solid neoplasm studies include National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Mayo Clinic.

Browse advanced malignant solid neoplasm trials by phase

Treatments under study

About Advanced Malignant Solid Neoplasm Clinical Trials

Looking for clinical trials for Advanced Malignant Solid Neoplasm? There are currently 29 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Malignant Solid Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Malignant Solid Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 37 trials

Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Not Applicable

Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person

Hematopoietic and Lymphatic System NeoplasmAdvanced Malignant Solid Neoplasm
Fred Hutchinson Cancer Center80 enrolled2 locationsNCT07141407
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Metastatic Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)105 enrolled182 locationsNCT05638295
Recruiting
Phase 1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8+35 more
M.D. Anderson Cancer Center54 enrolled1 locationNCT05039801
Recruiting
Phase 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more
Rahul Aggarwal89 enrolled3 locationsNCT03682289
Recruiting
Phase 2

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
M.D. Anderson Cancer Center13 enrolled1 locationNCT04879121
Recruiting
Phase 2

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)88 enrolled36 locationsNCT05327010
Recruiting
Phase 1

Studying TAK-243 in Patients With Advanced Cancer

Advanced Malignant Solid NeoplasmAdvanced Lymphoma
National Cancer Institute (NCI)95 enrolled1 locationNCT06223542
Recruiting
Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 1Phase 2

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)58 enrolled23 locationsNCT05691491
Recruiting
Phase 1Phase 2

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Locally Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8+6 more
National Cancer Institute (NCI)49 enrolled3 locationsNCT05053971
Recruiting
Phase 1

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Metastatic Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)35 enrolled1 locationNCT05691517
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)66 enrolled6 locationsNCT05687136
Recruiting
Phase 2

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI)115 enrolled1 locationNCT03907475
Recruiting
Phase 2

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Metastatic Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)500 enrolled27 locationsNCT06311214
Recruiting
Phase 1

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Pancreatic CancerLung CancerColon Cancer+3 more
RasCal Therapeutics, Inc.134 enrolled3 locationsNCT04678648
Recruiting
Phase 1

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center111 enrolled1 locationNCT04693468